{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:36:17Z","timestamp":1792089377133,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010051","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000}}],"reference-count":112,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010051.pub2","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T15:52:00Z","timestamp":1568389920000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Topical cyclosporine A therapy for dry eye syndrome"],"prefix":"10.1002","author":[{"given":"Cintia S","family":"de Paiva","sequence":"first","affiliation":[{"name":"Baylor College of Medicine; Ophthalmology; 6565 Fannin Street, NC 307 Houston Texas USA 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C","family":"Pflugfelder","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine; Ophthalmology; 6565 Fannin Street, NC 307 Houston Texas USA 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sueko M","family":"Ng","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health; Department of Epidemiology; 615 N. Wolfe Street, W5010 c\/o Cochrane Eyes and Vision Group Baltimore Maryland USA 21205"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen K","family":"Akpek","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine; Wilmer Eye Institute; 600 N. Wolfe Street, Maumenee #317 Baltimore Maryland USA 21287"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,13]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD010051.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/eye.2009.246","article-title":"Topical cyclosporine A for the dry eye findings of thyroid orbitopathy patients","volume":"24","author":"Altiparmak","year":"2010","journal-title":"Eye (London, England)"},{"issue":"10","key":"10.1002\/14651858.CD010051.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/bjo.2008.150011","article-title":"A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome","volume":"94","author":"Baiza-Dur\u00e1n","year":"2010","journal-title":"British Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1590\/S0034-72802009000200004","article-title":"Topical cyclosporine 0.05% for the treatment of dry eye disease in patients infected with the human immunodeficiency virus","volume":"68","author":"Barreto","year":"2009","journal-title":"Revista Brasileira de Oftalmologia"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5301\/ejo.5000952","article-title":"A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye","volume":"27","author":"Baudouin","year":"2017","journal-title":"European Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0005|cit5","first-page":"ARVO abstract 4","article-title":"Expression of inflammatory markers in dry eye syndrome following 12 months' treatment with topical cyclosporin","volume":"42","author":"Baudouin","year":"2001","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0006|cit6","first-page":"ARVO abstract 3","article-title":"Flow cytometric analysis of inflammatory markers in dry eyes: results of a six-month treatment with topical ciclosporin","volume":"41","author":"Baudouin","year":"2000","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"Pt B","key":"10.1002\/14651858.CD010051.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/978-1-4615-0717-8_107","article-title":"Flow cytometric analysis of the inflammatory marker HLA DR in dry eye syndrome: results from 12 months of randomized treatment with topical cyclosporin A","volume":"506","author":"Baudouin","year":"2002","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub2-BIB0008|cit8","first-page":"90","article-title":"Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A","volume":"42","author":"Brignole","year":"2001","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0009|cit9","first-page":"337","article-title":"Flow cytometry in impression cytology during keratoconjunctivitis sicca: effects of topical cyclosporin A on HLA DR expression","volume":"26","author":"Galatoire","year":"2003","journal-title":"Journal Francais d'Ophtalmologie"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jop.2009.0145","article-title":"A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial","volume":"26","author":"Chen","year":"2010","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3341\/kjo.2013.27.3.167","article-title":"The effect of topical cyclosporine 0.05% on dry eye after cataract surgery","volume":"27","author":"Chung","year":"2013","journal-title":"Korean Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/ICL.0b013e31822563be","article-title":"Effects of topical cyclosporine A plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome","volume":"37","author":"Demiryay","year":"2011","journal-title":"Eye & Contact Lens"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub2-BIB0013|cit13","first-page":"85","article-title":"Topical cyclosporine therapy for keratoconjunctivitis sicca in Sjogrens' syndrome","volume":"15","author":"Fan","year":"2003","journal-title":"Tzu Chi Medical Journal"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0014|cit14","first-page":"ARVO abstract 2","article-title":"A randomized double-masked clinical trial to assess efficacy and safety of a 1% CsA-containing ophthalmic ointment vs. placebo in patients with keratoconjunctivitis sicca (KCS) associated with Sj\u00f6gren's syndrome (SS)","volume":"37","author":"Foulks","year":"1996","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1755-3768.1994.tb02792.x","article-title":"Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sj\u00f6gren's syndrome","volume":"72","author":"G\u00fcnd\u00fcz","year":"1994","journal-title":"Acta Ophthalmologica"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1442-9071.2009.02090.x","article-title":"Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye","volume":"37","author":"Guzey","year":"2009","journal-title":"Clinical & Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1444-0938.2009.00369.x","article-title":"The effect of topical cyclosporine A treatment on corneal thickness in patients with trachomatous dry eye","volume":"92","author":"Guzey","year":"2009","journal-title":"Clinical & Experimental Optometry"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0018|cit18","first-page":"ARVO abstract 2","article-title":"A randomized double-masked clinical trial to assess the safety and comparative efficacy of three concentrations of a cyclosporine-containing ophthalmic ointment vs. placebo in patients with keratoconjunctivitis sicca (KCS)","volume":"37","author":"Helms","year":"1996","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF02697322","article-title":"Effect of topical cyclosporine on tear functions in tear-deficient dry eyes","volume":"39","author":"Jain","year":"2007","journal-title":"Annals of Ophthalmology (Skokie, Ill.)"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2008.08.015","article-title":"A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome","volume":"147","author":"Kim","year":"2009","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00003226-199307000-00007","article-title":"Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca","volume":"12","author":"Laibovitz","year":"1993","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0022|cit22","first-page":"ARVO abstract 5","article-title":"A randomized prospective clinical trial of the efficacy of cyclosporine ophthalmic emulsion 0.05% following trabeculectomy with antimetabolite","volume":"47","author":"Lankaranian","year":"2006","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"678","DOI":"10.5301\/ejo.5001002","article-title":"One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease","volume":"27","author":"Baudouin","year":"2017","journal-title":"European Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"European Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD010051.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ophtha.2012.03.017","article-title":"Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease","volume":"119","author":"Huang","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD010051.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ophtha.2012.01.028","article-title":"Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1\/2 trial","volume":"119","author":"Liew","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.optm.2006.04.078","article-title":"Topical 0.05% cyclosporine: effect on the quality of life of dry eye patients","volume":"77","author":"Lopez","year":"2006","journal-title":"Optometry"},{"issue":"7","key":"10.1002\/14651858.CD010051.pub2-BIB0028|cit28","first-page":"655","article-title":"Efficacy and safety of 0.05% cyclosporine A ophthalmic emulsion in treatment of dry eye","volume":"33","author":"Ma","year":"2015","journal-title":"Zhonghua Shiyan Yanke Zazhi [Chinese Journal of Experimental Ophthalmology]"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/ICO.0b013e31823cc098","article-title":"A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction","volume":"31","author":"Prabhasawat","year":"2012","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0030|cit30","unstructured":"Asano K Rao S Topical cyclosporine for the prevention of dry eye disease: second year of two-year study American Academy of Optometry Orlando (FL) 2009"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0031|cit31","unstructured":"Rao S Prevention of dry eye disease progression by topical cyclosporine 0.05% American Academy of Ophthalmology San Francisco (CA) 2008 202"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1089\/jop.2011.0073","article-title":"Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal","volume":"27","author":"Rao","year":"2011","journal-title":"Journal of Ocular Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0033|cit33","first-page":"ARVO abstract 2","article-title":"The impact of topical cyclosporine 0.05% on dry eye and daily activity","volume":"47","author":"Rao","year":"2006","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0034|cit34","first-page":"ARVO abstract 1","article-title":"Topical cyclosporine 0.05% for the prevention of dry eye disease progression","volume":"49","author":"Rao","year":"2008","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/jop.2009.0091","article-title":"Topical cyclosporine 0.05% for the prevention of dry eye disease progression","volume":"26","author":"Rao","year":"2010","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jcrs.2005.10.034","article-title":"Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis","volume":"32","author":"Salib","year":"2006","journal-title":"Journal of Cataract and Refractive Surgery"},{"issue":"10","key":"10.1002\/14651858.CD010051.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","article-title":"Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years","volume":"112","author":"Barber","year":"2005","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archopht.120.3.330","article-title":"Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine","volume":"120","author":"Kunert","year":"2002","journal-title":"Archives of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD010051.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","article-title":"Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes","volume":"118","author":"Kunert","year":"2000","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0041|cit40","doi-asserted-by":"crossref","unstructured":"Sall K Erratum: Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye diseases (Ophthalmology (2000) 107 (631-9)) Ophthalmology 2000 1220","DOI":"10.1016\/S0161-6420(99)00176-1"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0040|cit41","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/10807680260362696","article-title":"Blood concentrations of cyclosporin A during long-term treatment with cyclosporin A ophthalmic emulsions in patients with moderate to severe dry eye disease","volume":"18","author":"Small","year":"2002","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0043|cit43","first-page":"ARVO abstract 3","article-title":"Blood concentrations of cyclosporin A (CsA) during twice-daily treatment of 0.05% and 0.1% cyclosporine ophthalmic emulsions in patients with moderate to severe keratoconjunctivitis sicca","volume":"41","author":"Small","year":"2000","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00003226-200007000-00018","article-title":"Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion","volume":"19","author":"Turner","year":"2000","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0045|cit45","unstructured":"Whitcup SM Stern K Schiffman RM Topical cyclosporine 0.05% significantly improves Sj\u00f6gren's and non-Sj\u00f6gren's keratoconjunctivitis sicca American Academy of Ophthalmology San Francisco (CA) 2003 132"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Christensen M Hearn C Tudor M Stein J Meadows D Stone R Efficacy of a cyclosporine-based dry eye therapy with two marketed artificial tears as supportive therapy American Academy of Optometry Orlando (FL) 2004","DOI":"10.1016\/S1542-0124(12)70377-4"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0048|cit47","first-page":"ARVO abstract 2","article-title":"Efficacy and compatibility of an HP-guar based lubricant eye drop when used as supportive therapy with a cyclosporine-based ophthalmic emulsion","volume":"46","author":"Sall","year":"2005","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub2-BIB0047|cit48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.icl.0000170599.57728.29","article-title":"An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye","volume":"32","author":"Sall","year":"2006","journal-title":"Eye & Contact Lens"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub2-BIB0049|cit49","first-page":"548","article-title":"Topical cyclosporine A 0.05% in the treatment of keratoconjunctivitis sicca","volume":"229","author":"Schrell","year":"2012","journal-title":"Klinische Monatsblatter fur Augenheilkunde"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0050|cit50","first-page":"ARVO abstract 1","article-title":"The safety and efficacy of cyclosporine (0.05, 0.1, 0.2 and 0.4%) and vehicle ophthalmic emulsions in the treatment of moderate to severe keratoconjunctivitis sicca (KCS)","volume":"38","author":"Reis","year":"1997","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/978-1-4615-5359-5_138","article-title":"A dose-ranging clinical trial to assess the safety and efficacy of cyclosporine ophthalmic emulsion in patients with keratoconjunctivitis sicca. The Cyclosporine Study Group","volume":"438","author":"Tauber","year":"1998","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/ICL.0b013e3180676d44","article-title":"Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes","volume":"34","author":"Willen","year":"2008","journal-title":"Eye & Contact Lens"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub2-BIB0054|cit54","first-page":"389","article-title":"Effect of cyclosporin A in the treatment of severe dry eye syndrome","volume":"9","author":"Wu","year":"2009","journal-title":"International Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub2-BIB0055|cit55","first-page":"544","article-title":"Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline","volume":"8","author":"Arman","year":"2015","journal-title":"International Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD010051.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/ICO.0000000000000436","article-title":"Prospective randomized trial comparing efficacy of topical loteprednol etabonate 0.5% versus cyclosporine-A 0.05% for treatment of dry eye syndrome following hematopoietic stem cell transplantation","volume":"34","author":"Boynton","year":"2015","journal-title":"Cornea"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/IEB.0b013e3181ac94fb","article-title":"Topical cyclosporine (Restasis) cost-utility analysis","volume":"10","author":"Brown","year":"2009","journal-title":"Evidence-Based Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archophthalmol.2008.608","article-title":"Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome","volume":"127","author":"Brown","year":"2009","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10792-014-9901-4","article-title":"The efficacy of topical 0.05% cyclosporine A in patients with dry eye disease associated with Sjogren's syndrome","volume":"34","author":"Deveci","year":"2014","journal-title":"International Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0060|cit60","first-page":"E-Abstract 1066","article-title":"Efficacy of topical cyclosporine versus tears for improving visual outcomes following multifocal IOL implantation","volume":"48","author":"Donnenfeld","year":"2007","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD010051.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jcrs.2009.12.049","article-title":"Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation","volume":"36","author":"Donnenfeld","year":"2010","journal-title":"Journal of Cataract and Refractive Surgery"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jcrs.2012.11.024","article-title":"Topical cyclosporine A for postoperative photorefractive keratectomy and laser in situ keratomileusis","volume":"39","author":"Hessert","year":"2013","journal-title":"Journal of Cataract and Refractive Surgery"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0063|cit63","unstructured":"Hom M Comparison of cyclosporine A vs. rewetter for CL intolerance: a pilot study American Academy of Optometry Orlando (FL) 2004"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/01.icl.0000175651.30487.58","article-title":"Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients","volume":"32","author":"Hom","year":"2006","journal-title":"Eye & Contact Lens"},{"issue":"9","key":"10.1002\/14651858.CD010051.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/ICO.0000000000000165","article-title":"Efficacy of hypotonic 0.18% sodium hyaluronate eye drops in patients with dry eye disease","volume":"33","author":"Lee","year":"2014","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"8150757","DOI":"10.1155\/2016\/8150757","article-title":"Effectiveness and optical quality of topical 3.0% diquafosol versus 0.05% cyclosporine A in dry eye patients following cataract surgery","volume":"2016","author":"Lee","year":"2016","journal-title":"Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD010051.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1097\/MD.0000000000000551","article-title":"Topical fluorometholone treatment for ocular dryness in patients with Sj\u00f6gren syndrome: a randomized clinical trial in China","volume":"94","author":"Lin","year":"2015","journal-title":"Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3341\/kjo.2007.21.4.189","article-title":"Short term effects of topical cyclosporine and viscoelastic on the ocular surfaces in patients with dry eye","volume":"21","author":"Moon","year":"2007","journal-title":"Korean Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0069|cit69","unstructured":"Roberts C Carniglia P Brazzo B Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye American Academy of Optometry Orlando (FL) 2005"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0070|cit70","first-page":"ARVO abstract 2","article-title":"Comparison of cyclosporine to punctal plugs in relieving the signs and symptoms of dry eyes","volume":"46","author":"Roberts","year":"2005","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD010051.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/ICO.0b013e318074e460","article-title":"Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye","volume":"26","author":"Roberts","year":"2007","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0073|cit72","first-page":"ARVO abstract 2","article-title":"Dry eye symptoms following cataract surgery","volume":"47","author":"Roberts","year":"2006","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub2-BIB0072|cit73","first-page":"14","article-title":"Dry eye symptoms following cataract surgery","volume":"32","author":"Roberts","year":"2007","journal-title":"Insight (American Society of Ophthalmic Registered Nurses)"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0074|cit74","unstructured":"Schechter B Efficacy of topical cyclosporine 0.05% in the prevention of ocular surface inflammation secondary to pterygia American Academy of Ophthalmology San Francisco (CA) 2006 215"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0075|cit75","unstructured":"Perry HD Donnenfeld ED Manris PJG The effect of decreasing cyclosporine 0.05% on dry eye disease after one year of therapy American Academy of Ophthalmology San Francisco (CA) 2006 219"},{"issue":"10","key":"10.1002\/14651858.CD010051.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/ICO.0b013e318206caee","article-title":"The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy","volume":"30","author":"Su","year":"2011","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0077|cit77","first-page":"ARVO abstract 3","article-title":"The effect of decreasing cyclosporine 0.05% on dry eye disease after one year of therapy","volume":"48","author":"Su","year":"2007","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub2-BIB0078|cit78","first-page":"142","article-title":"Study on the treatment of dry eye with Loteprednol Etabonate","volume":"48","author":"Wan","year":"2012","journal-title":"Chung-Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.bmt.1705900","article-title":"Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease","volume":"41","author":"Wang","year":"2008","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0080|cit80","first-page":"E-abstract 2846","article-title":"Efficacy of cyclosporine A for the treatment of ocular rosacea","volume":"46","author":"Wittpenn","year":"2005","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0081|cit81","unstructured":"Schultze RL Michra G Comparison of topical cyclosporine (Restasis) and punctal occlusion in the treatment of dry eye syndrome American Academy of Ophthalmology San Francisco (CA) 2004 181"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0082|cit82","unstructured":"A multicenter, randomized, partial double blind, active control, parallel clinical trial to evaluate the efficacy, safety and usability of cyclosporin ophthalmic nanoemulsion 0.05% compared with cyclosporin ophthalmic emulsion 0.05% and diquafosol ophthalmic solution 3% Ongoing study October 2016 (first enrollment)"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0083|cit83","unstructured":"A randomized, multicenter, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 in the treatment of keratoconjunctivitis sicca Ongoing study February 2016"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0084|cit84","unstructured":"A multicenter, placebo controlled, Restasis referenced, randomized, double blind, Phase II study to evaluate the efficacy and safety of HU00701\/HU007 eye drops in patients with dry eye syndrome Ongoing study March 2016"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0085|cit85","unstructured":"CyclASol for the treatment of signs and symptoms of dry eye disease (DED) Ongoing study October 2017"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.ajo.2005.12.047","article-title":"Smoking associated with damage to the lipid layer of the ocular surface","volume":"141","author":"Altinors","year":"2006","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/mi.2010.82","article-title":"Homeostatic control of conjunctival mucosal goblet cells by NKT-derived IL-13","volume":"4","author":"Paiva","year":"2011","journal-title":"Mucosal Immunology"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0088|cit88","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0089|cit89","first-page":"337","article-title":"Flow cytometry in impression cytology during keratoconjunctivitis sicca: effects of topical cyclosporin A on HLA DR expression","volume":"26","author":"Galatoire","year":"2003","journal-title":"Journal Francais d'Ophtalmologie"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub2-BIB0090|cit90","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0091|cit91","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"10","key":"10.1002\/14651858.CD010051.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.ophtha.2018.03.039","article-title":"Effects of Prolonged Reading on Dry Eye","volume":"125","author":"Karakus","year":"2018","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD010051.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","article-title":"Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes","volume":"118","author":"Kunert","year":"2000","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archopht.120.3.330","article-title":"Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine","volume":"120","author":"Kunert","year":"2002","journal-title":"Archives of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1517\/14728214.2011.537824","article-title":"Emerging drugs for uveitis","volume":"16","author":"Larson","year":"2011","journal-title":"Expert opinion on emerging drugs"},{"issue":"Pt 1","key":"10.1002\/14651858.CD010051.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1042\/BJ20040669","article-title":"Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis","volume":"383","author":"Li","year":"2004","journal-title":"Biochemical Journal"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bjophthalmol-2015-308237","article-title":"Functional impairment of reading in patients with dry eye","volume":"101","author":"Mathews","year":"2017","journal-title":"British Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD010051.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/archopht.118.9.1264","article-title":"Prevalence of and risk factors for dry eye syndrome","volume":"118","author":"Moss","year":"2000","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archopht.122.3.369","article-title":"Incidence of dry eye in an older population","volume":"122","author":"Moss","year":"2004","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub2-BIB0100|cit100","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"12","key":"10.1002\/14651858.CD010051.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1097\/ICO.0000000000001350","article-title":"Gaps in current knowledge and priorities for future research in dry eye","volume":"36","author":"Saldanha","year":"2017","journal-title":"Cornea"},{"issue":"10","key":"10.1002\/14651858.CD010051.pub2-BIB0102|cit102","first-page":"1170","article-title":"Research questions and outcomes prioritized by patients with dry eye","volume":"136","author":"Saldanha","year":"2018","journal-title":"Journal of the American Medical Association Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0002-9394(03)00218-6","article-title":"Prevalence of dry eye syndrome among US women","volume":"136","author":"Schaumberg","year":"2003","journal-title":"American Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archophthalmol.2009.103","article-title":"Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies","volume":"127","author":"Schaumberg","year":"2009","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocular Surface"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/01.ico.0000133994.22392.47","article-title":"Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca","volume":"24","author":"Strong","year":"2005","journal-title":"Cornea"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/tvst.6.3.24","article-title":"Impact of glaucoma and dry eye on text-based searching","volume":"6","author":"Sun","year":"2017","journal-title":"Translational Vision Science and Technology"},{"issue":"12","key":"10.1002\/14651858.CD010051.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.ophtha.2011.05.029","article-title":"Prevalence and risk factors of dry eye disease in Japan: Koumi study","volume":"118","author":"Uchino","year":"2011","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/01.icl.0000252881.04636.5e","article-title":"Increased evaporative rates in laboratory testing conditions simulating airplane cabin relative humidity: an important factor for dry eye syndrome","volume":"33","author":"Uchiyama","year":"2007","journal-title":"Eye and Contact Lens"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjophthalmol-2013-303518","article-title":"Impact of dry eye on reading in a population-based sample of the elderly: the Salisbury Eye Evaluation","volume":"98","author":"Landingham","year":"2014","journal-title":"British Journal of Ophthalmology"},{"issue":"16","key":"10.1002\/14651858.CD010051.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2174\/0929867033457160","article-title":"Cyclophilin D as a drug target","volume":"10","author":"Waldmeier","year":"2003","journal-title":"Current Medicinal Chemistry"},{"issue":"9","key":"10.1002\/14651858.CD010051.pub2-BIB0112|cit112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010051","article-title":"Topical cyclosporine A therapy for dry eye syndrome","author":"Paiva","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010051.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD010051.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T18:04:25Z","timestamp":1664388265000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010051.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,13]]},"references-count":112,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010051.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,13]]}}}